1. Home
  2. AGD vs LUNG Comparison

AGD vs LUNG Comparison

Compare AGD & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGD
  • LUNG
  • Stock Information
  • Founded
  • AGD 2006
  • LUNG 1995
  • Country
  • AGD United Kingdom
  • LUNG United States
  • Employees
  • AGD N/A
  • LUNG N/A
  • Industry
  • AGD Trusts Except Educational Religious and Charitable
  • LUNG Industrial Specialties
  • Sector
  • AGD Finance
  • LUNG Health Care
  • Exchange
  • AGD Nasdaq
  • LUNG Nasdaq
  • Market Cap
  • AGD 263.6M
  • LUNG 124.0M
  • IPO Year
  • AGD N/A
  • LUNG 2020
  • Fundamental
  • Price
  • AGD $11.24
  • LUNG $2.75
  • Analyst Decision
  • AGD
  • LUNG Buy
  • Analyst Count
  • AGD 0
  • LUNG 6
  • Target Price
  • AGD N/A
  • LUNG $11.53
  • AVG Volume (30 Days)
  • AGD 61.2K
  • LUNG 322.4K
  • Earning Date
  • AGD 01-01-0001
  • LUNG 07-30-2025
  • Dividend Yield
  • AGD 8.13%
  • LUNG N/A
  • EPS Growth
  • AGD N/A
  • LUNG N/A
  • EPS
  • AGD N/A
  • LUNG N/A
  • Revenue
  • AGD N/A
  • LUNG $87,473,000.00
  • Revenue This Year
  • AGD N/A
  • LUNG $18.02
  • Revenue Next Year
  • AGD N/A
  • LUNG $18.17
  • P/E Ratio
  • AGD N/A
  • LUNG N/A
  • Revenue Growth
  • AGD N/A
  • LUNG 19.84
  • 52 Week Low
  • AGD $8.20
  • LUNG $2.50
  • 52 Week High
  • AGD $9.78
  • LUNG $9.37
  • Technical
  • Relative Strength Index (RSI)
  • AGD 71.70
  • LUNG 39.07
  • Support Level
  • AGD $11.15
  • LUNG $2.62
  • Resistance Level
  • AGD $11.25
  • LUNG $2.88
  • Average True Range (ATR)
  • AGD 0.10
  • LUNG 0.17
  • MACD
  • AGD 0.01
  • LUNG 0.05
  • Stochastic Oscillator
  • AGD 98.77
  • LUNG 39.68

About AGD abrdn Global Dynamic Dividend Fund of Beneficial Interest

Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors among others.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: